Analysts from Jefferies (Wall Street's famous investment bank) pointed out last week that the National Institute of Health and Clinical Excellence (NICE) of the NHS in the UK conducted a simulated valuation analysis that CAR-T therapy is used to treat children. In patients with acute lymphoblastic leukemia (ALL), it is reasonable to set a maximum price of $649,000.
However, the above assessment does not mean that companies such as Novartis and Kite can be priced according to this standard after their CAR-T therapy is approved for treatment of ALL. Jeffrey's analysts said that $649,000 is almost the price cap for KTE-C19 (Kite Pharmaceuticals Inc.), the first to submit a non-Hodgkin's lymphoma listing application.
Jeffrey's analysts also raised the price forecast for KTE-C19 in the US from $200,000 to $300,000, and raised its price in Europe from $125,000 to $204,000.
Jeffrey's analysts pointed out that this price assessment has certain limitations. This clinical value-based price assessment only considers children and adolescent ALL patients. If elderly patients are taken into account, they will get a lower reasonable price. . A Novartis spokesperson commented: "It is still too early to discuss these issues. We will consider pricing issues when the drugs are approved for listing.
At the beginning of this year, Novartis submitted to the FDA a CTL-01 application for the treatment of relapsed or refractory B cell ALL in children and adolescents. At the end of the year, Novartis plans to submit a CTL019 treatment for adult diffuse large B-cell lymphoma to the FDA, and submit a CTL019 application for treatment of these two indications to the EMA.
In December last year, a phase II trial published by Novartis at the ASH2016 conference showed that 50 patients with relapsed or refractory B-cell ALL in children and adolescents received CTL019 for 3 months, and 41 patients achieved complete remission or no blood count. full recovery. According to data released by Kite, 9 patients with ALL and children with ALL underwent KTE-C19 treatment, and 9 patients achieved complete remission.
A reasonable price is that each quality-adjusted life year costs no more than £50,000, and the NHS estimate is equivalent to assuming that the CAR-T therapy can bring 11 quality-adjusted life years, 10 years more than the current standard therapy.
Hotel Safes,Electronic Lock Safes,Fireproof Box Smart Safe,Hot Sale Home Safes
Hebei Tiger Brand Group Jia Bao Cabinet Industry Co. LTD , https://www.cntigersafe.com